Home
Deutsch
Advanced Search
Browse by ...
Publication overview
Contact persons
Help
Publ. Version/Full Text
Preprint
Research data
DOI
PMC
 |
|
Open Access Green as soon as Postprint is submitted to ZB.
CNS-targeting pharmacological interventions for the metabolic syndrome.
J. Clin. Invest. 130, 4058-4071 (2019)
Publ. Version/Full Text
Preprint
Research data
DOI
PMC
The metabolic syndrome (MetS) encompasses medical conditions such as obesity, hyperglycemia, high blood pressure, and dyslipidemia that are major drivers for the ever-increasing prevalence of type 2 diabetes, cardiovascular diseases, and certain types of cancer. At the core of clinical strategies against the MetS is weight loss, induced by bariatric surgery, lifestyle changes based on calorie reduction and exercise, or pharmacology. This Review summarizes the past, current, and future efforts of targeting the MetS by pharmacological agents. Major emphasis is given to drugs that target the CNS as a key denominator for obesity and its comorbid sequelae.
Altmetric
Additional Metrics?
Edit extra informations
Login
Publication type
Article: Journal article
Document type
Review
Keywords
Glucagon-like Peptide-1; Controlled-release Phentermine/topiramate; Dependent Insulinotropic Peptide; Cannabinoid-1 Receptor Blocker; Melanin-concentrating Hormone; Neurons Regulate Energy; Once-daily Liraglutide; Diet-induced Obesity; Food-intake; Weight-loss
ISSN (print) / ISBN
0021-9738
e-ISSN
1558-8238
Quellenangaben
Volume: 130,
Issue: 10,
Pages: 4058-4071
Publisher
American Society of Clinical Investigation
Publishing Place
2015 Manchester Rd, Ann Arbor, Mi 48104 Usa
Non-patent literature
Publications
Reviewing status
Peer reviewed
Institute(s)
Institute of Diabetes and Obesity (IDO)